British National Formulary October 2025 Update

This update contains 10 significant changes, 3 new monographs and 1 deleted monograph

 

Significant Changes:

• Charcoal, activated: name change to activated charcoal.
• Cholestasis: updated guidance on intrahepatic cholestasis of pregnancy.
• Conjugated oestrogens (equine): name change to conjugated oestrogens.
• Digoxin-specific antibody: name change to digoxin-specific antibody fragments.
• Factor VIII fraction, dried: name change to factor VIII.
• Factor XIII fraction, dried: name change to factor XIII.
• Fenfluramine: new indication and dose for Lennox-Gastaut syndrome and update to structure of existing dosing for Dravet syndrome.
• Guidance included on biotin interference with laboratory tests (advice in levothyroxine sodium, liothyronine sodium, parenteral nutrition supplements, vitamins with minerals and trace elements; see example in levothyroxine sodium).
• Mirikizumab: new indication and dose for Crohn’s disease.
• Ruxolitinib: new indication and dose for graft-versus-host disease.

 

New Monographs:

• Alyftrek® [deutivacaftor with tezacaftor and vanzacaftor].
• Filspari® [sparsentan].
• Hympavzi® [marstacimab].

 

Deleted Monographs: Hepatitis A with typhoid vaccine.